Candriam Luxembourg S.C.A. lifted its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 16.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 510,000 shares of the company’s stock after purchasing an additional 72,000 shares during the quarter. Candriam Luxembourg S.C.A. owned about 1.08% of Karyopharm Therapeutics worth $5,600,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Voya Investment Management LLC lifted its position in Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after acquiring an additional 4,444 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $136,000. Trexquant Investment LP bought a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $202,000. American International Group Inc. lifted its position in Karyopharm Therapeutics by 20.9% in the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after acquiring an additional 2,836 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $235,000. 59.23% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the sale, the director now directly owns 2,882 shares in the company, valued at approximately $31,702. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Christopher Brett Primiano sold 4,958 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total value of $55,777.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,653 shares of company stock valued at $174,728. Company insiders own 14.71% of the company’s stock.

WARNING: “Candriam Luxembourg S.C.A. Has $5.60 Million Stake in Karyopharm Therapeutics Inc. (KPTI)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/13/candriam-luxembourg-s-c-a-has-5-60-million-stake-in-karyopharm-therapeutics-inc-kpti.html.

KPTI has been the topic of several analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $19.00 price objective (up from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. BidaskClub raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. ValuEngine cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $15.50.

Shares of Karyopharm Therapeutics Inc. (NASDAQ KPTI) traded up $0.14 on Monday, reaching $10.91. 96,500 shares of the company’s stock were exchanged, compared to its average volume of 244,349. Karyopharm Therapeutics Inc. has a 1-year low of $7.48 and a 1-year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities research analysts predict that Karyopharm Therapeutics Inc. will post -2.58 earnings per share for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.